IP Library › Granted Patent US 9,492,563
Granted Patent B2
US 9,492,563 · App. 14/067,819 · Granted Nov 15, 2016

Antibody/drug conjugates and methods of use

Inventors: Carola Leuschner (Baton Rouge, LA); Hector Alila (Baton Rouge, LA)
Assignee: ESPERANCE PHARMACEUTICALS, INC.
A61K47/48438A61K47/48561C07K16/2887C07K16/32C07K2317/622
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,492,563
App. No.
14/067,819
Granted
Nov 15, 2016
Kind
B2
Abstract

The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.

Claims (31)

1. An antibody conjugate, comprising an antibody that binds to CD20 or CD19, wherein the antibody is linked to two or more lytic domains, wherein said lytic domains comprises or consists of a peptide selected from KFAKFAKKFAKFAKK, KFAKFAKKFAKFAKKF, KFAKFAKKFAKFAKKFA, KFAKFAKKFAKFAKKFAK, KFAKFAKKFAKFAKKFAKF and KFAKFAKKFAKFAKKFAKFA (SEQ. ID. NOs. 1-6, respectively), or a peptide selected from KFAKFAKKFAKFAKK, KFAKFAKKFAKFAKKF, KFAKFAKKFAKFAKKFA, KFAKFAKKFAKFAKKFAK, KFAKFAKKFAKFAKKFAKF and KFAKFAKKFAKFAKKFAKFA (SEQ. ID. NOs. 1-6, respectively) having one or more of the F, A, or K residues of the lytic domain substituted with a corresponding D-amino acid; and wherein one of said lytic domains is linked to the amino(NH 2 )-terminus of a Light (L) chain of the antibody, and the other of said lytic domains is linked to the amino(NH 2 )-terminus of a Heavy (H) chain of the antibody.

2. A polypeptide conjugate, comprising a Heavy (H) chain and a Light (L) chain of an antibody that binds to CD20 or CD19, wherein the Heavy (H) and Light (L) chain variable regions each comprise 3 CDRs, wherein the amino(NH 2 )-terminus of the Light (L) chain is linked to a lytic domain, wherein the amino(NH 2 )-terminus of the Heavy (H) chain is linked to a lytic domain, and wherein said lytic domains comprise or consist of a peptide selected from KFAKFAKKFAKFAKK, KFAKFAKKFAKFAKKF, KFAKFAKKFAKFAKKFA, KFAKFAKKFAKFAKKFAK, KFAKFAKKFAKFAKKFAKF and KFAKFAKKFAKFAKKFAKFA (SEQ. ID. NOs. 1-6, respectively), or a peptide selected from KFAKFAKKFAKFAKK, KFAKFAKKFAKFAKKF, KFAKFAKKFAKFAKKFA, KFAKFAKKFAKFAKKFAK, KFAKFAKKFAKFAKKFAKF and KFAKFAKKFAKFAKKFAKFA (SEQ. ID. NOs. 1-6, respectively) having one or more of F, A, or K residues of the lytic domain substituted with a corresponding D-amino acid.

3. The conjugate of claim 1 or 2 , further comprising a lytic domain linked to the carboxy(C)-terminus of the Heavy (H) chain.

4. The conjugate of claim 1 or 2 , further comprising a lytic domain linked to the carboxy(C)-terminus of the Light (L) chain.

5. The conjugate of claim 1 or 2 , wherein the conjugate comprises a plurality of lytic domains linked to the Heavy (H) chain and Light (L) chain, wherein at least one of the lytic domains is linked to the amino(NH 2 )-terminus of the Heavy (H) chain, and at least one of the lytic domains is linked to the carboxy(C)-terminus of the Heavy (H) chain or is linked to the carboxy(C)-terminus of the Light (L) chain.

6. The conjugate of claim 1 or 2 , comprising three, four, five, six, seven or eight lytic domains linked to the Heavy (H) chain or Light (L) chain.

7. The conjugate of claim 6 , wherein the lytic domains are linked to the amino(NH 2 )-terminus of the Light (L) chains, and have the identical amino acid sequence.

8. The conjugate of claim 1 or 2 , wherein said lytic domain linked to the amino(NH 2 )-terminus of the Light (L) chain is joined to said Light (L) chain immediately after the last amino acid at the amino(NH 2 )-terminus of the Light (L) chain, thereby forming a continuous amino acid sequence between the lytic domain and the Light (L) chain.

9. The conjugate of claim 1 or 2 , wherein said Light (L) chain and said lytic domain linked to the amino(NH 2 )-terminus of the Light (L) chain are joined by a covalent bond, peptide sequence or a non-peptide linker or spacer.

10. The conjugate of claim 9 , wherein said linker or spacer comprises a linear carbon chain.

11. The conjugate of claim 1 or 2 , wherein said lytic domain consists of a sequence from about 10 to about 15 L- or D-amino acids, about 15 to about 20 L- or D-amino acids, about 10 to about 28 L- or D-amino acids, about 10 to about 50 L- or D-amino acids.

12. The conjugate of claim 1 or 2 , wherein the lytic domain linked to the amino(NH 2 )-terminus of the Light (L) chain is cationic.

13. The conjugate of claim 1 or 2 , wherein the lytic domain linked to the amino(NH 2 )-terminus of the Light (L) chain forms an amphipathic alpha helical structure.

14. The conjugate of claim 1 or 2 , wherein the conjugate binds to CD20.

15. The conjugate of claim 1 , wherein the antibody comprises an antibody fragment or subsequence that comprises Heavy (H) and Light (L) chain variable regions each comprising 3 CDRs of an antibody that binds to CD20 or CD19.

16. The conjugate of claim 15 , wherein said antibody fragment or subsequence comprises an Fab, Fab′, F(ab′) 2 , Fv, Fd, single-chain Fv (scFv), disulfide-linked Fvs (sdFv), V L , V H , Camel Ig, V-NAR, VHH, trispecific (Fab 3 ), bispecific (Fab 2 ), diabody ((V L -V H ) 2 or (V H —V L ) 2 ), triabody (trivalent), tetrabody (tetravalent), minibody ((scF v -C H 3) 2 ), bispecific single-chain Fv (Bis-scFv), IgGdeltaC H 2, scFv-Fc, (scFv) 2 -Fc, affibody, aptamer, avimer or nanobody.

17. The conjugate of claim 1 or 2 , wherein said antibody is a monoclonal antibody.

18. The conjugate of claim 1 or 2 , wherein said Heavy (H) chain or Light (L) chain is selected from a Heavy (H) chain or Light (L) chain of an antibody that binds to CD20 or has all 3 CDR sequences of an antibody that binds to CD20 set forth in any of Table C or Examples 14, 15, 18, 20 or 21.

19. The conjugate of claim 1 or 2 , wherein said conjugate comprises any Heavy (H) chain conjugate, any Light (L) chain conjugate, any whole antibody conjugate sequence of an antibody that binds to CD20 set forth in any of Table C or Examples 14, 15, 18, 20 or 21.

20. The conjugate of claim 1 or 2 , wherein said CD19 comprises all or a portion of SEQ ID NO:132 or wherein said CD20 comprises all or a portion of SEWQ ID NO:133.

21. The conjugate of claim 1 or 2 wherein said CD19 or CD20 is expressed by or on a cell.

22. The conjugate of claim 1 or 2 , wherein said antibody or polypeptide conjugate is isolated or purified.

23. A composition comprising the conjugate of claim 1 or 2 , and an anti-cell proliferative or immune stimulating agent.

24. A polypeptide comprising a: lytic domain linked to the amino(NH 2 )-terminus of the Light (L) chain of an antibody that binds to CD20 or CD19 and a lytic domain linked to the amino(NH 2 )-terminus of the Heavy (H) chain of an antibody that binds to CD20 or CD19, wherein one of said lytic domains comprise or consist of a peptide selected from KFAKFAKKFAKFAKK, KFAKFAKKFAKFAKKF, KFAKFAKKFAKFAKKFA, KFAKFAKKFAKFAKKFAK, KFAKFAKKFAKFAKKFAKF and KFAKFAKKFAKFAKKFAKFA (SEQ. ID. NOs.1-6, respectively), or a peptide selected from KFAKFAKKFAKFAKK, KFAKFAKKFAKFAKKF, KFAKFAKKFAKFAKKFA, KFAKFAKKFAKFAKKFAK, KFAKFAKKFAKFAKKFAKF and KFAKFAKKFAKFAKKFAKFA (SEQ. ID. NOs.1-6, respectively) and optionally having one or more of the F, A, or K residues substituted with a corresponding D-amino acid.

25. A polypeptide comprising two or more lytic domains, wherein the two lytic domains are each linked to the amino(NH 2 )-terminus of the Light (L) chains of an antibody that binds to CD20; and a Heavy (H) chain of an antibody that binds to CD20, wherein said Heavy (H) chain and said Light (L) chains have all 3 CDR sequences of an antibody that binds to CD20 set forth in any of Table C or Examples 14, 15, 18, 20 or 21.

26. A method of reducing or inhibiting proliferation of a neoplastic, tumor, cancer or malignant cell, comprising contacting the cell with the conjugate of claim 1 or 2 or polypeptide of claim 24 or 25 in an amount sufficient to reduce or inhibit proliferation of the neoplastic, tumor, cancer or malignant cell.

27. A method of treating a subject having a hyperproliferative disorder, comprising administering to the subject an amount of the conjugate of claim 1 or 2 or polypeptide of claim 24 or 25 sufficient to treat the hyperproliferative disorder.

28. A method of treating a subject having a neoplasia, tumor, cancer or malignancy, comprising administering to the subject an amount of the conjugate of claim 1 or 2 or polypeptide of claim 24 or 25 sufficient to reduce or inhibit proliferation of the neoplasia, tumor, cancer or malignancy.

29. The conjugate of claim 6 , wherein the lytic domains linked to the amino(NH 2 )-terminus of the Light (L) chains have a different amino acid sequence.

30. The conjugate of claim 1 or 2 , wherein the antibody binds to CD20.

31. The conjugate of claim 1 or 2 , wherein the antibody binds to CD19.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2022
From: ESPERANCE PHARMACEUTICALS INC.
To: A28 THERAPEUTICS INC.
Reel/Frame 059971/0741 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2014
From: LEUSCHNER, CAROLA; ALILA, HECTOR
To: ESPERANCE PHARMACEUTICALS, INC.
Reel/Frame 031944/0564 →
Continuity (2)
Provisional Application 61720257 · Oct 30, 2012
Related Publication 20140127241A1 · May 8, 2014